Tissue and Data Acquisition and Analysis Resource

发现导致恶性表型的基因表达的关键变化 长期以来，这一直是基础和临床科学中生物医学研究人员的目标。我们学到了很多 关于使用模型系统(组织培养和动物)的疾病机制，但翻译 人类临床疾病的模型系统中的发现并不是最理想的。后者至少在#年到期。 部分原因是人类临床疾病的复杂性，这是由大量基因引起的，这些基因是 活跃的细胞代谢和与个体患者疾病相关的共病，这可能 改变或偏向疾病过程的表型。高通量测试方法的发展 例如用于测量基因表达、染色体杂交和单个DNA芯片技术 核苷酸多态在一定程度上解决了细胞水平上的生物复杂性问题。 然而，获得临床共同发病率和治疗数据可能会影响患者的预后，并可能 细胞代谢的影响变化更加困难，因为它依赖于各种人工人类记录和 报告系统。 组织和数据采集与分析核心(TDAAC)的目标是获取人类 样本和相关的临床和病理结果，以支持目标的翻译研究 疾病。为此，它支持IRB批准的《组织采集系统支持癌症》协议 研究“(TASSCR)以及其他研究人员发起的IRB批准的协议，以支持特定的 调查性问题。因为TDAAC是专注于基因的多中心资助的产物 多种肿瘤表型的表达芯片研究，部分样本具有相关基因 将表达式数据作为其批注的一部分。TDAAC教职员工通过以下途径支持翻译研究 利用患者知情在高道德标准下获取带注释的组织和血液样本 同意和处理标本，使标本用于病人护理的主要目的是 标本的质量对于生物医学研究来说是最理想的。

Identification of critical changes in gene expression that are responsible for the malignant phenotype has long been the goal of biomedical researchers in the basic and clinical sciences. Much has been learned concerning disease mechanism using model systems (tissue culture and animals) but the translation of findings in model systems to human clinical disease has been less than optimal. The latter is due at least in part to the complexity of human clinical disease which results from the vast number of genes which are active in cellular metabolism and the co-morbidities associated with an individual patient's disease which can alter or bias the phenotype of the disease process. The development of high throughput testing methods such as DMA chip technologies for measuring gene expression, chromosomal hybridization and single nucleotide polymporphisms has in part addressed the issue of biological complexity at the cellular level. However, acquiring clinical co-morbidity and treatment data that is likely to affect patient outcome and may impact changes in cellular metabolism is more difficult as it relies on various manual human recording and reporting systems. The Tissue and Data Acquisition and Analysis Core (TDAAC) has as its goal the acquisition of human specimens and associated clinical and pathologic findings to support translational research of the target disease. To this end it supports an IRB approved protocol "Tissue Acquisition System to Support Cancer Research" (TASSCR) as well as other investigator initiated IRB approved protocols to support specific investigative questions. Because TDAAC is an outgrowth of a multicenter grant that focused on gene expression microarray studies on multiple cancer phenotypes, some samples have associated gene expression data as a part of their annotation. TDAAC faculty and staff support translational research through acquisition of annotated tissue and blood samples under high ethical standards utilizing patient informed consent and treatment of specimens such that the primary purpose of the specimen for patient care is maintained and the quality of the specimen is optimal for biomedical research.